Norovirus

Overview
Pathogen Biology
Transmission & Epidemiology
Symptoms & Clinical Course
Diagnosis
Treatment
Home & Supportive Care
Complications
Prevention
Key Research Papers
Connections
Featured Videos

1. Overview

Norovirus is the leading cause of acute gastroenteritis ("stomach flu") worldwide, responsible for approximately 685 million cases of illness and 212,000 deaths globally each year. It affects people of all ages and is notorious for its extraordinary contagiousness — as few as 18 viral particles are sufficient to cause infection — and its ability to trigger explosive outbreaks in closed settings such as cruise ships, nursing homes, schools, hospitals, and restaurants.

Formerly known as Norwalk virus (named after an outbreak in Norwalk, Ohio in 1968), norovirus belongs to the family Caliciviridae. The illness is characterized by the sudden onset of nausea, vomiting, diarrhea, and abdominal cramping, typically lasting 1–3 days in healthy adults. Despite its brief duration, norovirus causes enormous economic burden through healthcare costs, lost productivity, and disruption of food service and institutional operations.

There is currently no approved vaccine or antiviral drug for norovirus. Management is entirely supportive — hydration is the cornerstone. Prevention relies on rigorous hand hygiene (soap and water, not alcohol gel alone), surface disinfection with bleach-based products, and isolation of ill individuals.

2. Pathogen Biology

Norovirus is a non-enveloped, positive-sense single-stranded RNA virus with a genome of approximately 7.5 kb, encoding three open reading frames (ORFs). ORF1 encodes the non-structural polyprotein (including the RNA-dependent RNA polymerase, RdRp, and helicase). ORF2 encodes the major capsid protein VP1, which mediates host cell attachment and is the primary target of neutralizing antibodies. ORF3 encodes a minor structural protein VP2.

Genogroups and Genotypes

Noroviruses are classified into at least 10 genogroups (GI–GX) based on VP1 sequence divergence. Genogroups GI, GII, and GIV infect humans; genogroups GIII, GV, and GVI infect animals. GII.4 is the predominant human genotype, responsible for the majority of outbreaks since the 1990s. GII.4 variants emerge every 2–3 years as new strains escape population immunity — a pattern of "epochal evolution" analogous in some respects to influenza drift.

Histo-Blood Group Antigens (HBGAs) as Receptors

VP1 binds to histo-blood group antigens (HBGAs) expressed on gastrointestinal epithelial cells and in secretions. HBGAs include ABO, Lewis, and secretor blood group antigens. Individuals who are "non-secretors" (lacking a functional FUT2 gene) do not express HBGAs in the intestinal mucosa and are substantially protected from GII.4 norovirus infection — a natural genetic resistance affecting approximately 20% of Northern Europeans.

Mechanism of Pathogenesis

Norovirus infects jejunal epithelial cells and enterocytes. In the absence of a reliable in vitro cell culture system (human intestinal enteroids, HIEs, have recently enabled direct culture), pathogenesis data come primarily from human challenge studies and animal models. Infection causes blunting of intestinal villi, crypt hyperplasia, and loss of brush border enzymes — producing a transient malabsorptive state. The virus does not invade beyond the intestinal epithelium. Histologically, the gastric mucosa is intact, which makes "gastritis" a misnomer; the correct term is acute viral gastroenteritis affecting the small intestine.

3. Transmission & Epidemiology

Routes of Transmission

Norovirus spreads with remarkable efficiency via multiple routes:

Fecal-oral: Ingestion of fecally contaminated food or water is the most common route. A single gram of stool from a norovirus-infected person contains up to 5 billion viral particles; only ~18 particles cause infection.
Person-to-person contact: Direct contact with an infected person or contaminated surfaces (fomites); norovirus survives on hard surfaces for days to weeks and is resistant to drying.
Aerosol/vomitus: Projectile vomiting generates aerosols that can spread virus to nearby persons and contaminate surfaces up to 7–8 meters away. This is a major amplification factor in closed settings.
Contaminated shellfish: Oysters and other bivalve mollusks filter-feed and bioaccumulate norovirus from polluted water to very high concentrations; eating raw or undercooked shellfish is a classic exposure.

Environmental Stability

Norovirus is exceptionally stable in the environment: survives freezing, survives heat up to 60°C (partially survives 72°C), resists chlorine concentrations used in drinking water (though not food-contact surface disinfection with 1000+ ppm bleach), and can survive for weeks to months on surfaces. Alcohol-based hand sanitizers are effective at reducing viral load but are less reliable than soap and water at removing and inactivating norovirus.

Global Burden and Seasonality

Norovirus accounts for approximately 18% of all acute gastroenteritis cases worldwide. In high-income countries, norovirus is the dominant cause of foodborne illness outbreaks. It is more common in winter months (hence the colloquial name "winter vomiting bug") in temperate climates, though transmission occurs year-round. Nursing home, hospital, and long-term care facility outbreaks are particularly problematic due to the vulnerability of elderly residents to dehydration.

4. Symptoms & Clinical Course

The incubation period is 12–48 hours (typically 24–48 hours). Onset is abrupt, often described by patients as "it hit me out of nowhere."

Cardinal Symptoms

Nausea: Usually the first symptom; often severe, waves of nausea preceding vomiting.
Vomiting: Prominent and often projectile; may occur multiple times per hour in the acute phase. In young children, vomiting may predominate over diarrhea.
Diarrhea: Watery, non-bloody, non-mucoid; typically 4–8 episodes per day. Adults tend to have more diarrhea than vomiting compared to children.
Abdominal cramping: Often severe; crampy, diffuse.
Low-grade fever: Present in approximately 40% of cases; high fever is unusual and should prompt evaluation for other diagnoses.
Myalgia and headache: Common systemic symptoms, contributing to the illness feeling worse than "just a stomach bug."

Duration and Shedding

The acute illness typically resolves within 24–72 hours. Viral shedding in stool, however, continues for 2–4 weeks after symptom resolution in immunocompetent adults (and can persist for months in immunocompromised individuals). This prolonged shedding without symptoms drives ongoing transmission in households and care settings.

Immunity and Re-infection

Immunity after norovirus infection is serotype-specific, short-lived (protection against re-infection by the same strain lasts ~6–14 months), and incomplete against heterologous strains. Individuals can therefore be infected multiple times throughout life — there is no durable cross-protective immunity.

5. Diagnosis

In otherwise healthy individuals with a classic clinical presentation (abrupt onset nausea/vomiting/diarrhea, no blood in stool, short duration, known exposure or community outbreak), norovirus gastroenteritis is diagnosed clinically without laboratory testing. Testing is important in outbreak investigation, hospitalized patients, immunocompromised individuals, and when other diagnoses need exclusion.

PCR (RT-PCR) — Gold Standard

Reverse transcriptase-PCR on stool is the most sensitive and specific test, detecting and genotyping norovirus; sensitivity >95%. Turnaround time varies by laboratory (hours to 1–2 days). Preferred method for outbreak confirmation and clinical diagnosis when testing is warranted.

Rapid Antigen Tests

Immunochromatographic antigen detection tests (e.g., BioSign Norovirus) are faster (<30 minutes) but significantly less sensitive than PCR (sensitivity ~50–70%), particularly for GI genotypes and low-inoculum samples. Useful for rapid outbreak screening, but a negative result does not exclude norovirus.

Electron Microscopy

Historically used to identify norovirus morphology in stool; largely replaced by PCR except in reference laboratories. Classic norovirus particles have a characteristic "feathery" surface texture in negative-staining electron microscopy.

What to Rule Out

When symptoms are prolonged (>3 days), when fever is high, or when blood or mucus is present in stool, consider stool culture for bacterial pathogens (Salmonella, Campylobacter, Shigella, STEC E. coli), Clostridioides difficile toxin testing (especially in recent antibiotic users), and rotavirus testing in children under 5.

6. Treatment

There is no antiviral therapy approved for norovirus infection. Treatment is entirely supportive. The small molecule inhibitor nitazoxanide has been studied but shows inconsistent efficacy. Research into antivirals targeting the RdRp and capsid is ongoing but no drug has cleared clinical trial requirements.

Antibiotics are not indicated and will not shorten the illness; they should only be used if a concurrent bacterial infection is confirmed. Antiemetics (ondansetron, promethazine) may be used to reduce vomiting and facilitate oral rehydration, particularly in children. Loperamide (for diarrhea) may be used cautiously in adults but is not recommended in children with severe illness.

7. Home & Supportive Care

For the vast majority of healthy adults and older children, norovirus gastroenteritis is managed at home with attention to hydration:

Fluid replacement is the priority: Oral rehydration solution (ORS — glucose and electrolytes formulated for optimal intestinal absorption) is ideal. Commercial ORS (Pedialyte, Hydralyte, Liquid IV), homemade ORS (1 liter water, 6 teaspoons sugar, half teaspoon salt), or diluted sports drinks. Sip small amounts frequently rather than large gulps, which can trigger vomiting.
Sip after vomiting: Wait 20–30 minutes after vomiting, then start sipping 1–2 tablespoons of fluid every 5 minutes; gradually increase volume as tolerated.
Ice chips: Excellent for the first hour or two when vomiting is most active — easier to tolerate than liquids.
Diet when eating resumes: The BRAT diet (bananas, rice, applesauce, toast) is traditional; evidence for specific dietary restrictions is weak, but bland, low-fat, low-fiber foods are easiest to tolerate. Avoid dairy, high-fat, or high-sugar foods in the first 24 hours.
Avoid alcohol and NSAIDs during the acute phase; both can irritate a healing intestinal mucosa.
Rest: Symptoms are fatiguing; rest facilitates recovery.
Warning signs to seek medical attention: Signs of dehydration (no urination in 8 hours, dry mouth, no tears, dizziness when standing), inability to keep any fluid down for 8 hours, fever above 38.9°C, blood in stool or vomit, symptoms lasting more than 3 days, or any severe illness in elderly or immunocompromised individuals.

Preventing Spread at Home

The ill person should stay home for at least 48 hours after symptoms resolve. Dedicated bathroom use if possible; if shared, clean the toilet seat, handle, and surrounding surfaces with a diluted bleach solution (1:10 to 1:50 household bleach in water) after each use. Wash hands with soap and water (not just sanitizer) after bathroom use and before food preparation. Machine wash contaminated clothing and bedding on the hottest cycle.

8. Complications

Dehydration: The most common complication, particularly dangerous in infants, toddlers, elderly adults, and immunocompromised patients. Severe dehydration requires IV fluid replacement (isotonic crystalloid, 20 mL/kg boluses in children).
Electrolyte imbalance: Hyponatremia (from hypotonic fluid replacement) and hypokalemia from prolonged diarrhea and vomiting; can cause muscle cramps, weakness, and cardiac arrhythmia in severe cases.
Chronic norovirus infection in immunocompromised patients: Solid organ transplant recipients, HIV patients, and patients on immunosuppressive therapy can develop persistent, chronic norovirus infection lasting months to years — associated with progressive malnutrition, weight loss, intestinal villous atrophy, and reduced graft function in transplant recipients. A major clinical challenge with no approved treatment; reduction of immunosuppression may allow clearance.
Necrotizing enterocolitis (NEC): Norovirus has been implicated in NEC in premature neonates — a rare but life-threatening complication.
Outbreak-related mortality: Case fatality in healthy adults is negligible; in nursing home residents, outbreaks carry a significant mortality burden in those too frail to tolerate dehydration.

9. Prevention

Given the absence of a vaccine, prevention relies on behavioral and environmental measures:

Hand Hygiene

Washing hands with soap and water for at least 20 seconds is the single most effective personal prevention measure. Alcohol-based hand sanitizers reduce but do not eliminate norovirus; they are an adjunct, not a substitute for soap-and-water handwashing when hands may be contaminated. Wash hands before food preparation, before eating, after using the toilet, and after caring for someone who is ill.

Surface Disinfection

Norovirus is resistant to many common disinfectants. Effective options include diluted household bleach (1,000–5,000 ppm sodium hypochlorite), commercial EPA-registered disinfectants with norovirus activity, and accelerated hydrogen peroxide products. Alcohol-based disinfectants (<70% ethanol) are less reliable against the non-enveloped norovirus.

Food Safety

Cook shellfish to internal temperature of at least 63°C (145°F); this inactivates norovirus in most shellfish (oysters require cooking to 90°C internal temperature). Wash produce thoroughly. Food handlers who are ill or within 48 hours of recovery must not handle food. Norovirus can contaminate produce at the farm level via irrigation water — wash all fresh fruits and vegetables under running water.

Outbreak Control in Institutions

Cohort ill residents/patients; exclude ill staff for 48 hours after symptom resolution; implement enhanced cleaning protocols; restrict movement between wards; consider closing affected wards to new admissions; contact local public health authorities for outbreak management guidance.

Vaccine Development

No licensed vaccine is available. Multiple candidates are in clinical trials, primarily targeting GII.4 capsid antigens. The genetic diversity and rapid evolution of norovirus (analogous to influenza drift) poses a significant vaccine development challenge. Promising VLP-based and bivalent (GI + GII) vaccine candidates have demonstrated immunogenicity in phase 2 trials.

10. Key Research Papers

Patel MM, Widdowson MA, Glass RI, et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008;14:1224–1231. PMID: 18799183.
Lopman BA, Steele D, Kirkwood CD, Parashar UD. The vast and varied global burden of norovirus: prospects for prevention and control. PLOS Med. 2016;13:e1001999. PMID: 27404293.
Karst SM, Wobus CE, Goodfellow IG, et al. Advances in norovirus biology. Cell Host Microbe. 2014;15:668–680. PMID: 24922571.
Lay MK, Atmar RL, Guix S, et al. Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology. 2010;406:1–11. PMID: 20478603.
Atmar RL, Estes MK. The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am. 2006;35:275–290. PMID: 16880065.
Robilotti E, Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 2015;28:134–164. PMID: 25567225.
Ettayebi K, Crawford SE, Murakami K, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016;353:1387–1393. PMID: 27562956.
Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001–2007. J Infect Dis. 2009;200:802–812. PMID: 19627229.
Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9:548–553. PMID: 12692541.
Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015;211:870–878. PMID: 25371534.
Mubareka S, Lowen AC, Steel J, et al. Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis. (comparative context) PMID: 19210163.
Widdowson MA, Sulka A, Bulens SN, et al. Norovirus and foodborne disease, United States, 1991–2000. Emerg Infect Dis. 2005;11:95–102. PMID: 15705329.

Live PubMed Searches

Back to Table of Contents

Connections